

**Amendments to the Specification:**

**On page 1, after the title, please insert the following paragraph:**

The present application is a continuation application of U.S. Application No. 09/646,785, filed February 16, 2001, which is a U.S. National Phase Application of International Application PCT/JP99/01448, filed March 23, 1999, which claims the benefit of Japanese Patent Application No. P1998-095448, filed March 24, 1998, all of which are herein incorporated by reference in their entirety

**Please replace the paragraph on page 15, lines 5-14 with the following amended paragraph:**

Also, the amino acid sequence of SDF-1, which is a ligand binding to CXCR4, has already been known. There are two types of SDF-1 differing in the length of amino acid sequence, *i.e.*, SDF-1- $\alpha$  and SDF-1- $\beta$ . Specifically, the amino acid sequence of human SDF-1- $\alpha$  is set forth in SEQ ID NO: 5 and its base sequence in SEQ ID NO: 6 (base positions 474-740). Human SDF-1- $\beta$  [~~(SEQ ID NO: 9)~~] is derived from human SDF-1- $\alpha$  by appending four amino acid residues, Arg Phe Lys Met (SEQ ID NO: 9), to a C-terminus thereof.

**Please replace the paragraph on page 15, lines 15-22 with the following amended paragraph:**

The amino acid sequence of murine SDF-1- $\alpha$  is set forth in SEQ ID NO: 7 and its base sequence in SEQ ID NO: 8 (base positions 82-348). Murine SDF-1- $\beta$  [~~(SEQ ID NO: 10)~~] is derived from murine SDF-1- $\alpha$  by appending four amino acid residues, Arg Leu Lys Met (SEQ ID NO: 10), to a C-terminus thereof. For human and murine SDF-1's, the sequence of from the 1st amino acid (Met) to the 21st amino acid (Gly) is a signal sequence.

**Please delete the previous sequence listing and substitute therefore new pages 1-8 which comprise the paper copy of the corrected Sequence Listing and renumber them accordingly.**